Tezacaftor / ivacaftor · Symdeko

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Cystic Fibrosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
EU
  • Cystic fibrosis in combination with ivacaftor; sold in the EU as Symkevi
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Phase 2 (3)
Cystic Fibrosis
NCT04006873 · Nottingham University Hospitals NHS Trust
2019-09-03 – 2020-10-29 · Cystic Fibrosis
What this study did
NCT02730208 · Vertex Pharmaceuticals Incorporated
2016-09 – 2018-07 · Cystic Fibrosis
What this study did
NCT02508207 · Vertex Pharmaceuticals Incorporated
2016-02 – 2017-06 · Cystic Fibrosis
What this study did
Phase 1 (1)
Cystic Fibrosis
NCT03587961 · George Solomon
2019-08-01 – 2027-09-01 · Cystic Fibrosis
What this study did
Phase 4 (1)
Cystic Fibrosis
NCT03624101 · University of Alabama at Birmingham
2018-12-01 – 2019-10-03 · Cystic Fibrosis
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tezacaftor / Ivacaftor (Symdeko): this drugApprovedSmall moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
Elexacaftor / Tezacaftor / Ivacaftor (Trikafta)ApprovedSmall moleculeCFTR, CFTRReliable signal
NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results).
NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results).
Ivacaftor (Kalydeco)ApprovedSmall moleculeCFTRPartial signal
NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1)
NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7)
Lumacaftor (Orkambi)ApprovedSmall moleculeCFTRReliable signalNo reviewed efficacy summary in this indication
Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek)ApprovedSmall moleculeCFTR, CFTRReliable signalNo reviewed efficacy summary in this indication
KB407Phase 1Gene therapy / editingCFTR (gene replacement)not yet gradedNo reviewed efficacy summary in this indication
VX-828Phase 1Small moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
LuvomeranDiscontinuedRNA / oligonucleotideCFTR (mRNA replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Symdeko (Tezacaftor / ivacaftor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 1Cystic FibrosisRecruiting
Est. primary completion 2027-01-01 · NCT03587961 · CT.gov ↗
What to watch

See the full readout calendar ↗